GlassScriptPhysician profile
John A Vollmer
NPI 1932113628
$1,256.58
in general payments reported to CMS, 2019-2025
17 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2024: $746 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $363.71 | 2024-2025 | Breztri |
| Novo Nordisk INC | $244.69 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $144.10 | 2022-2025 | Evenity, Prolia, Repatha |
| Janssen Biotech, INC. | $88.20 | 2024 | Darzalex, Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.53 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $66.60 | 2022 | |
| Janssen Scientific Affairs, LLC | $45.42 | 2025 | Tremfya |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.21 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $34.48 | 2022 | |
| Pfizer INC. | $28.75 | 2024 | |
| Lilly USA, LLC | $28.35 | 2022 | |
| Astellas Pharma US INC | $27.01 | 2024 | Veozah |
| Ibsa Pharma INC. | $16.37 | 2022 | |
| Bardy Diagnostics, INC. | $15.14 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2024 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $13.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vollmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.